Latest news with #medicaldevice
Yahoo
2 days ago
- Business
- Yahoo
Revvity Stock Sinks on Lowered China Immunodiagnostics Outlook
Revvity (RVTY) was one of the worst-performing stocks in the S&P 500 Monday after the medical device maker said it anticipated a "meaningful pullback" in its immunodiagnostics business in China. The Waltham, Mass.-based company reported second-quarter adjusted earnings per share of $1.18 on revenue that rose 4% year-over-year to $720.3 million. Both topped consensus estimates of analysts surveyed by Visible Alpha. However, Revvity lowered its full-year adjusted EPS outlook to a range of $4.85 to $4.95 from the prior $4.90 to $5.00. On the earnings call, CEO Prahlad Singh said that the company now is "expecting a fairly meaningful pullback in our immunodiagnostics business in China, which is incorporated into our updated outlook for the total company for the year," according to a transcript provided by AlphaSense. Revvity shares dropped close to 8% in recent trading and have lost about 14% of their value in 2025. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Business
- Yahoo
MEDevice Silicon Valley 2025 Engineers Connections Through Multidimensional Approach
SANTA CLARA, CA / / July 28, 2025 / MEDevice Silicon Valley, the premier West Coast event connecting medical device engineers and cutting-edge MedTech companies, is set to deliver its most dynamic and transformative event yet. Positioned at the heart of California's $32.6 billion MedTech economy and 83,000-strong industry workforce, MEDevice Silicon Valley has evolved into an electrifying catalyst for breakthrough collaborations. The 2025 edition, taking place November 19-20 at the Santa Clara Convention Center, promises an expanded and curated experience designed to showcase innovation at every stage of medical device development lifecycle. Registration is now open. "We're not just hosting an event, we're igniting a movement," declares Melissa Magestro, Vice President, Informa Markets Engineering. "MEDevice has been completely reimagined to create powerful connections that spark immediate solutions and drive long-term industry transformation. Every element has been strategically designed to deliver exceptional value and measurable impact." Education sessions at MEDevice Silicon Valley continue to push boundaries through daily keynotes diving into topics on sustainability, manufacturing and the future of medtech. Attendees will have access to a dynamic lineup of new show floor theaters, including the Investment Theater, Design Studio, Innovation Spotlight Theater and Trends and Technology Theater, each offering expert insights and real-world perspectives. Complementing the thought leadership are additional hands-on workshops covering cybersecurity, regulatory compliance and product development, while intimate Fireside Chats invite candid conversations around challenges shaping the industry. The exhibit hall delivers deepened engagement with guided tours tailored around top areas of interest and emerging solutions, discovering what is new from exhibiting companies such as Medbio, Accumold, Westpak and Canon USA. The MEDevice Innovation Center launches, housing Device Diaries, Tech Lab and Innovation Showcase, spotlighting breakthrough ideas. Start-ups can gain visibility in the dedicated pavilion and Investor Lounge, offering platforms for visibility and investment. Research highlights with local universities and startups further demonstrate the event's commitment to collaboration and discovery. Strategic networking formats designed for intentional interactions include topic-focused roundtables and Quick-Connect speed networking sessions. Debuting this year, the Hosted Buyer Program will facilitate productive one-on-one meetings between 40 of the top original equipment manufacturer (OEM) engineers, decision-makers and vetted suppliers, enabling participants to achieve ROI through targeted conversations that advance business objectives. MEDevice Silicon Valley stands at the heart of one of the most vibrant medical device technology ecosystems, creating a more immersive, purposeful environment for professionals across the industry landscape. To register, visit: About MEDeviceMEDevice, an MD&M event, is the leading North American event brand for the medical technology industry, connecting engineers and cutting-edge medtech companies annually in the most prominent U.S. healthcare hubs. Visitors at the MEDevice events will learn from hands-on demos, presentations from OEMs, keynote presentations, innovation showcases, an all-new medical adhesives pavilion, matchmaking and networking opportunities. MEDevice is organized by Informa Markets Engineering and includes MEDevice Boston and MEDevice Silicon Valley, as well as MD&M West, MD&M South, MD&M Minneapolis and MD&M East. Official listed media partners include Medical Device & Diagnostic Industry (MD+DI) and DesignNews. For more information, please visit About Informa Markets EngineeringInforma Markets Engineering, a subsidiary of Informa plc (LON:INF), portfolio is the leading B2B event producer, publisher, and digital media business for the world's $3-trillion advanced, technology-based manufacturing industry. Our print and electronic products deliver trusted information to the engineering market and leverage our proprietary 1.3-million-name database to connect suppliers with buyers and purchase influencers. We produce more than 50 events and conferences in a dozen countries, connecting manufacturing professionals from around the globe. The Engineering portfolio is organized by Informa, the world's leading exhibitions organizer that brings a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, please visit Media ContactInforma Markets Engineering EngineeringPR@ SOURCE: INFORMA MARKETS - ENGINEERING View the original press release on ACCESS Newswire Sign in to access your portfolio
Yahoo
2 days ago
- Business
- Yahoo
Canaccord Downgrades Globus Medical (GMED) PT to $90, Maintains Buy Rating
Globus Medical Inc. (NYSE:GMED) is one of the most undervalued stocks to buy and hold for 3 years. On July 22, Canaccord reduced its price target for Globus Medical from $97 to $90 while maintaining a Buy rating. The adjustment showed Canaccord's updated financial model following the preliminary Q2 2025 results. The preliminary results showed revenues that align with both Canaccord's and the Street's consensus expectations. In Q1 2025, the company reported revenue of $598 million, which was a decrease of 0.8% on a constant currency basis. Non-GAAP EPS increased by 9% year-over-year to $0.68. Free cash flow saw a significant increase of 493% year-over-year, reaching $141 million. The US Spine business showed 2% growth in Q1, while international spine implant growth was 1% on a constant currency basis. Enabling Technology sales, however, decreased by 31% compared to the prior year, and the combined Trauma and NSO business declined by 8% in Q1. A closeup shot of a laboratory technician handling a medical device used for fertility treatments. The company launched two new products in Q1 2025 aimed at supporting market penetration and product portfolio. The US spine business exhibited resilience with 2% growth, driven by high retention rates. Globus Medical Inc. (NYSE:GMED) is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the US and internationally. While we acknowledge the potential of GMED as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Business
- Yahoo
OSR Holdings to acquire South Korea's medical device company Woori IO
Healthcare business OSR Holdings (OSRH) has signed a term sheet to acquire South Korea's medical device company, Woori IO (WORIO). Under the agreement, WORIO will be acquired by OSRH's Korean affiliate, OSR Holdings Co., Ltd (OSRK). WORIO will become OSRK's wholly owned subsidiary, with the shareholders of the former receiving new OSRK shares. These shares may be convertible into OSRH common stock on Nasdaq, subject to a $10 per OSRH share condition and other terms. WORIO shareholders have the option of converting their OSRK shares into OSRH shares at a fixed ratio. This conversion is contingent upon OSRH's stock price, hitting a minimum of $10.00 at any point within three years after the term sheet is executed. Should this price target not be achieved within the specified timeframe, both parties are committed to entering into renegotiations. A six-month exclusivity period is part of the agreement, during which OSRK will carry out confirmatory legal and financial due diligence. The goal is to conclude the acquisition within this timeframe. Via its subsidiaries, OSRH is involved in various healthcare sectors, including regenerative biologics, immuno-oncology, and the distribution of medical devices. OSRH CEO Peter Hwang said: "We believe this initial milestone with Woori IO aligns strongly with our mission to accelerate breakthrough healthcare innovations with global impact. "Woori IO's breakthrough noninvasive glucose monitoring platform, coupled with its high-profile partnership with global companies, puts OSRH in a position to become a first mover in this fast-growing global market." WORIO's platform is said to leverage near-infrared spectroscopy (NIRS) for the measurement of glucose levels, eliminating the need for finger pricks from diabetes patients. The technology has already undergone a proof-of-concept trial with the Korea University Hospital (Guro) to validate its prototype devices. WORIO is preparing for a larger confirmatory study to seek approval from the Korean Ministry of Food and Drug Safety (MFDS). The company's technology is also seen as a potential addition to wearable glucose monitoring devices such as smartwatches. "OSR Holdings to acquire South Korea's medical device company Woori IO" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Washington Post
3 days ago
- Health
- Washington Post
NIH cuts spotlight a hidden crisis facing patients with experimental brain implants
Carol Seeger finally escaped her debilitating depression with an experimental treatment that placed electrodes in her brain and a pacemaker-like device in her chest. But when its batteries stopped working, insurance wouldn't pay to fix the problem and she sank back into a dangerous darkness. She worried for her life, asking herself: 'Why am I putting myself through this?'
